Next Article in Journal
Poly (Lactic-Co-Glycolic) Acid–Poly (Vinyl Pyrrolidone) Hybrid Nanoparticles to Improve the Efficiency of Oral Delivery of β-Carotene
Previous Article in Journal
Formation of Ciprofloxacin–Isonicotinic Acid Cocrystal Using Mechanochemical Synthesis Routes—An Investigation into Critical Process Parameters
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

Retraction: Hellinen et al. Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics 2019, 11, 412

1
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland
2
Drug Research Programme, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland
3
Laboratory of Biohybrid Technologies, Institute of Chemistry, St. Petersburg State University, Peterhof, 198504 St. Petersburg, Russia
4
Institute of Clinical Medicine, Department of Ophthalmology, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(3), 635; https://doi.org/10.3390/pharmaceutics14030635
Submission received: 28 February 2022 / Accepted: 8 March 2022 / Published: 14 March 2022
The published article [1] has been retracted due to data errors. During a review of the data, the authors found that the studied LEPI-1 cell line is not derived from the ARPE-19 RPE cell line of the human origin as described in the article but rather originates from the Madin-Darby canine (Canis familiaris) kidney cell line with the human MDR1 gene (MDCK-MDR1). This incorrect interpretation of the cell origin was a consequence of cell line cross-contamination and an error in characterization process.
The outcome and conclusions of the study were affected, so it was decided that a correction would not be appropriate, and the paper will therefore be retracted. We apologize for any inconvenience caused by the removal of this article.
To ensure the addition of only high quality scientific works to the field of scholarly publication, this article [1] is retracted and shall be marked accordingly. We apologize to the readers of Pharmaceutics.

Reference

  1. Hellinen, L.; Pirskanen, L.; Tengvall-Unadike, U.; Urtti, A.; Reinisalo, M. Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics 2019, 11, 412. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hellinen, L.; Pirskanen, L.; Tengvall-Unadike, U.; Urtti, A.; Reinisalo, M. Retraction: Hellinen et al. Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics 2019, 11, 412. Pharmaceutics 2022, 14, 635. https://doi.org/10.3390/pharmaceutics14030635

AMA Style

Hellinen L, Pirskanen L, Tengvall-Unadike U, Urtti A, Reinisalo M. Retraction: Hellinen et al. Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics 2019, 11, 412. Pharmaceutics. 2022; 14(3):635. https://doi.org/10.3390/pharmaceutics14030635

Chicago/Turabian Style

Hellinen, Laura, Lea Pirskanen, Unni Tengvall-Unadike, Arto Urtti, and Mika Reinisalo. 2022. "Retraction: Hellinen et al. Retinal Pigment Epithelial Cell Line with Fast Differentiation and Improved Barrier Properties. Pharmaceutics 2019, 11, 412" Pharmaceutics 14, no. 3: 635. https://doi.org/10.3390/pharmaceutics14030635

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop